Switch theme
Sign up to access all valuation multiples
PT Darya-Varia Laboratoria Tbk (Darya-Varia) is operating in the pharmaceutical industry. It is engaged in the manufacture and trade of pharmaceutical products, human, traditional medicines, pharmaceutical materials, raw materials for traditional medicines, inorganic base chemicals, organic base chemicals, equipment for surgery, medical and dental care, medical and dental equipment, orthopedic equipment, prosthetic, eyeglasses, laboratory and health equipment from glass, cosmetics; wholesaler of pharmaceutical, traditional medicine, chemical base materials, laboratory equipment, cosmetic; wholesale trade in pharmaceuticals; laboratory testing services, health support service activities, research and development, periodic inspection services, and many more activities.
1976
1.7K+
LTM Revenue n/a
LTM EBITDA n/a
$76.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Darya-Varia Laboratoria has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Darya-Varia Laboratoria achieved revenue of $125M and an EBITDA of $14.8M.
Darya-Varia Laboratoria expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Darya-Varia Laboratoria valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $114M | $125M | XXX | XXX | XXX |
| Gross Profit | $60.5M | $58.6M | XXX | XXX | XXX |
| Gross Margin | 53% | 47% | XXX | XXX | XXX |
| EBITDA | $13.6M | $14.8M | XXX | XXX | XXX |
| EBITDA Margin | 12% | 12% | XXX | XXX | XXX |
| Net Profit | $9.0M | $8.8M | XXX | XXX | XXX |
| Net Margin | 8% | 7% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Darya-Varia Laboratoria's stock price is IDR 1450 (or $0).
Darya-Varia Laboratoria has current market cap of IDR 1.62T (or $97.6M), and EV of IDR 1.27T (or $76.1M).
See Darya-Varia Laboratoria trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $76.1M | $97.6M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Darya-Varia Laboratoria has market cap of $97.6M and EV of $76.1M.
Darya-Varia Laboratoria's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Darya-Varia Laboratoria's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Darya-Varia Laboratoria and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $76.1M | XXX | XXX | XXX |
| EV/Revenue | 0.6x | XXX | XXX | XXX |
| EV/EBITDA | 5.1x | XXX | XXX | XXX |
| P/E | 10.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 5.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpDarya-Varia Laboratoria's NTM/LTM revenue growth is n/a
Darya-Varia Laboratoria's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $32K for the same period.
Over next 12 months, Darya-Varia Laboratoria's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Darya-Varia Laboratoria's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Darya-Varia Laboratoria and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $32K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 20% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 43% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Darya-Varia Laboratoria acquired XXX companies to date.
Last acquisition by Darya-Varia Laboratoria was XXXXXXXX, XXXXX XXXXX XXXXXX . Darya-Varia Laboratoria acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Darya-Varia Laboratoria founded? | Darya-Varia Laboratoria was founded in 1976. |
| Where is Darya-Varia Laboratoria headquartered? | Darya-Varia Laboratoria is headquartered in Indonesia. |
| How many employees does Darya-Varia Laboratoria have? | As of today, Darya-Varia Laboratoria has 1.7K+ employees. |
| Is Darya-Varia Laboratoria publicy listed? | Yes, Darya-Varia Laboratoria is a public company listed on IDX. |
| What is the stock symbol of Darya-Varia Laboratoria? | Darya-Varia Laboratoria trades under DVLA ticker. |
| When did Darya-Varia Laboratoria go public? | Darya-Varia Laboratoria went public in 1994. |
| Who are competitors of Darya-Varia Laboratoria? | Similar companies to Darya-Varia Laboratoria include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Darya-Varia Laboratoria? | Darya-Varia Laboratoria's current market cap is $97.6M |
| What is the current revenue growth of Darya-Varia Laboratoria? | Darya-Varia Laboratoria revenue growth between 2023 and 2024 was 10%. |
| Is Darya-Varia Laboratoria profitable? | Yes, Darya-Varia Laboratoria is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
